Stopping rules and estimation problems in clinical trials
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Stopping rules in clinical trials can lead to bias in point estimation of the magnitude of treatment difference. A simulation exercise, based on estimation of the risk ratio in a typical post‐myocardial infarction trial, examines the nature of this exaggeration of treatment effect under various group sequential plans and also under continuous naive monitoring for statistical significance. For a fixed treatment effect the median bias in group sequential design is small, but it is greatest for effects that the trial has reasonable power to detect. Bias is evidently greater in trials that stop early and is dramatic under naive monitoring for significance. Group sequential plans lead to a multimodal sampling distribution of treatment effect, which poses problems for incorporating their estimates into meta‐analyses. By simulating a population of trials with treatment effects modelled by an underlying distribution of true risk ratios, a Bayesian method is proposed for assessing the plausible range of true treatment effect for any trial based on interim results. This approach is particularly useful for producing shrinkage of the unexpectedly large and imprecise observed treatment effects that arise in clinical trials that stop early. Its implications for trial design are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Group sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Self-citationFreiman, J. A., Chalmers, T. C., Smith, H., & Kuebler, R. R. (1978) · New England Journal of Medicine · doi:10.1056/nejm197809282991304 · Cited by 1,628
Cited by
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Self-citationMoher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2012) · International Journal of Surgery · doi:10.1016/j.ijsu.2011.10.001 · Cited by 2,345
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.004 · Cited by 1,858
(1990) · New England Journal of Medicine · doi:10.1056/nejm199011293232201 · Cited by 1,530
Why Most Discovered True Associations Are Inflated
Ioannidis, J. P. A. (2008) · Epidemiology · doi:10.1097/ede.0b013e31818131e7 · Cited by 1,495
“This is performed according to robust rules that suggest termination when a demanding threshold of statistical significance is crossed during an interim analysis.(3,4) These interventions are indeed effective (the null of “no effectiveness” is correctly rejected).”
BackgroundMethodCan trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?
Thorlund, K., Devereaux, P. J., Wetterslev, J., Guyatt, G., Ioannidis, J. P. A., Thabane, L., Gluud, L.-L., Als-Nielsen, B., & Gluud, C. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyn179 · Cited by 833
Bayesian methods in health technology assessment: a review.
Spiegelhalter, Myles, Jones, & Abrams (2000) · Health Technology Assessment · doi:10.3310/hta4380 · Cited by 358
Issues in data monitoring and interim analysis of trials
Grant, A., Altman, D., Babiker, A., Campbell, M., Clemens, F., Darbyshire, J., Elbourne, D., McLeer, S., Parmar, M., Pocock, S., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9070 · Cited by 269
Self-citationMeta‐research: The art of getting it wrong
Ioannidis, J. P. A. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.19 · Cited by 227
“Early stopping leads to exaggerated estimates of effect sizes (Bassler et al., 2010; Hughes and Pocock, 1988; Montori et al., 2005; Pocock and Hughes, 1989).”
BackgroundThe search for evidence of effective health promotion
Speller, V., Learmonth, A., & Harrison, D. (1997) · BMJ · doi:10.1136/bmj.315.7104.361 · Cited by 171
Early stopping of randomized clinical trials for overt efficacy is problematic.
Bassler, D., Montori, V. M., Briel, M., Glasziou, P., & Guyatt, G. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.07.016 · Cited by 130
The alpha spending function approach to interim data analyses
DeMets, D. L., & Lan, G. (1995) · Cancer Treatment and Research · doi:10.1007/978-1-4615-2009-2_1 · Cited by 58
Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., et al. (2020) · Trials · doi:10.1186/s13063-020-04334-x · Cited by 58
Floriani, I., Rotmensz, N., Albertazzi, E., Torri, V., De Rosa, M., Tomino, C., & de Braud, F. (2008) · Trials · doi:10.1186/1745-6215-9-46 · Cited by 8
“On the other hand, conducting an interim analysis may also have drawbacks, since immature results on small numbers of patients will provide imprecise or even biased point and interval estimates of the treatment effect, increasing the error in inferential process [3]: when a clinical trial is closed because a treatment…”
Background
Metadata
- Authors
- Hughes, M. D., & Pocock, S. J.
- Venue
- Statistics in Medicine
- Publisher
- Wiley
- Published
- 1988-12
- Volume
- 7
- Issue
- 12
- Pages
- 1231-1242
- ISSN
- 0277-6715 (ISSN-L)
- 1097-0258
- OpenAlex
- W2086407709
- Cited by
- 127
- References
- 4
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.